🇺🇸 FDA
Pipeline program

LIBTAYO 350 mg concentrate for solution for infusion., M1774, M1774, M1774

MS201924_0022

Phase 2 small_molecule active

Quick answer

LIBTAYO 350 mg concentrate for solution for infusion., M1774, M1774, M1774 for Non-Squamous Non-Small Cell Lung Cancer is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Non-Squamous Non-Small Cell Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials